{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:03:32Z","timestamp":1760853812918},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T00:00:00Z","timestamp":1411603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0108166","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T19:36:36Z","timestamp":1411673796000},"page":"e108166","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of a Novel Anti-Cancer Compound for Astrocytomas"],"prefix":"10.1371","volume":"9","author":[{"given":"Sang Y.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Slagle-Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-Shu","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,9,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010","volume":"15","author":"QT Ostrom","year":"2013","journal-title":"Neuro Oncol"},{"key":"ref2","unstructured":"American Cancer Society (2012) Cancer Facts & Figures 2012. Atlanta: American Cancer Society. Available: http:\/\/www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2012\/<\/ext-link>."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"R Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11940-011-0130-0","article-title":"High-Grade Gliomas","volume":"13","author":"BJ Theeler","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2176\/nmc.50.713","article-title":"Standard therapy for glioblastoma \u2013 a review of wehere we are","volume":"50","author":"R Nishikawa","year":"2010","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref6","first-page":"2585","article-title":"TMZ and treatment of malignant glioma","volume":"6","author":"HS Friedman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11864-005-0002-5","article-title":"Treatment of metastatic malignant melanoma","volume":"6","author":"E Atallah","year":"2005","journal-title":"Curr Treat Options Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002800051027","article-title":"A phase II study of TMZ in hormone-refractory prostate cancer","volume":"45","author":"JP van Brussel","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1006043332368","article-title":"A phase II study of TMZ in advanced untreated pancreatic cancer","volume":"16","author":"MJ Moore","year":"1998","journal-title":"Invest New drugs"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijrobp.2008.11.032","article-title":"Preoperative intensity-modulated radiotherapy combined with TMZ for locally advanced soft-tissue sarcoma","volume":"75","author":"J Jakob","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","first-page":"160","article-title":"A phase II trial of oral TMZ in patients with metastatic renal cell cancer","volume":"50","author":"DK Park","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","article-title":"Triazene compounds: mechanism of action and related DNA repair systems","volume":"56","author":"F Marchesi","year":"2007","journal-title":"Pharmacol Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.1998.16.12.3851","article-title":"DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma","volume":"16","author":"HS Friedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"ME Hegi","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment","volume":"13","author":"DP Cahill","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"S Yip","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mrfmmm.2007.06.009","article-title":"DNA topoisomerase II, genotoxicity, and cancer","volume":"623","author":"AK McClendon","year":"2007","journal-title":"Mutat Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"JJ Champoux","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"ref19","unstructured":"Beck WT (1996) DNA topoisomerases and tumor cell resistance to their inhibitors. In: Schilsky R, Milano G, Ratain M, editors. Principles of Antineoplastic Drug Development and Pharmacology (Basic and Clinical Oncology). CRC Press. 487\u2013502."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.4161\/cc.6.14.4495","article-title":"Molecular and structural transactions at human DNA replication origins","volume":"6","author":"A Falaschi","year":"2007","journal-title":"Cell Cycle"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1227\/NEU.0b013e3182233e24","article-title":"Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan","volume":"69","author":"JN Bruce","year":"2011","journal-title":"Neurosurgery"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pbc.22690","article-title":"A phase II study of metronomic oral topotecan for recurrent childhood brain tumors","volume":"56","author":"JE Minturn","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2152\/jmi.52.41","article-title":"Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2","volume":"52","author":"Y Matsumoto","year":"2005","journal-title":"J Med Invest"},{"key":"ref24","first-page":"4203","article-title":"Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor)","volume":"25","author":"Y Chen","year":"2005","journal-title":"Anticancer Res"},{"key":"ref25","first-page":"1061","article-title":"The topoisomerase II inhibitor, genistein, induces G2\/M arrest and apoptosis in human malignant glioma cell lines","volume":"19","author":"F Schmidt","year":"2008","journal-title":"Oncol Rep"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/ijc.25888","article-title":"HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A","volume":"129","author":"SY Lee","year":"2011","journal-title":"Int J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"27905","DOI":"10.1074\/jbc.M702672200","article-title":"Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation","volume":"282","author":"SF de Almeida","year":"2007","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"13161","DOI":"10.1074\/jbc.M110.170944","article-title":"Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability","volume":"286","author":"Y Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1096\/fj.06-6397com","article-title":"Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE","volume":"21","author":"SY Lee","year":"2007","journal-title":"FASEB J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/mol.105.018978","article-title":"3,3\u2032-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells","volume":"69","author":"Y Gong","year":"2006","journal-title":"Mol Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jmb.2012.07.014","article-title":"The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage","volume":"424","author":"TJ Wendorff","year":"2012","journal-title":"J Mol Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"RA Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"TA Halgren","year":"2004","journal-title":"J Med Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11060-011-0787-y","article-title":"MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors","volume":"107","author":"M Mellai","year":"2012","journal-title":"J Neurooncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/sj.bjc.6601193","article-title":"Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to TMZ","volume":"89","author":"T Kanzawa","year":"2003","journal-title":"Br J Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3171\/jns.2007.106.4.646","article-title":"Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on TMZ-resistant glioma cells","volume":"106","author":"M Uzzaman","year":"2007","journal-title":"J Neurosurg"},{"key":"ref37","first-page":"248","article-title":"Antiinflammatory activity of the new aminomethyl derivatives of 1-cyclohexyl-5-alkyl and 1-cyclohexyl-5,5-dialklbarbituric acids","volume":"35","author":"B Cebo","year":"1980","journal-title":"Farmaco Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/0006-2952(85)90335-1","article-title":"5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agent","volume":"34","author":"AD Brewer","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.bmcl.2009.04.014","article-title":"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids-identification of highly promising leads","volume":"19","author":"P Singh","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"ref40","article-title":"Crystal structure and antitumor activity of the novel zwitterionic complex of tri-n-butyltin(IV) with 2-thiobarbituric acid","author":"VI Balas","year":"2008","journal-title":"Bioinorg Chem Appl"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.ejmech.2011.04.005","article-title":"Synthesis, structural characterization and biological studies of the triphenyltin(IV) complex with 2-thiobarbituric acid","volume":"46","author":"VI Balas","year":"2011","journal-title":"Eur J Med Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1016\/j.bmcl.2009.04.132","article-title":"Exploration of novel thiobarbituric acid-, rhodanine- and thiohydrantoin-based HIV-1 integrase inhibitors","volume":"19","author":"S Rajamaki","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1743-422X-8-18","article-title":"Characterization of thiobarbituric acid derivatives as inhibitors of hepatitis C virus NS5B polymerase","volume":"8","author":"JH Lee","year":"2011","journal-title":"Virol J"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/0026-0495(89)90215-1","article-title":"Induction of profound hypouricemia by a non-sedating thiobarbiturate","volume":"38","author":"RP Warrell Jr","year":"1989","journal-title":"Metabolism"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00203538","article-title":"Merbarone: an antitumor agent entering clinical trials","volume":"5","author":"A Glover","year":"1987","journal-title":"Invest New Drugs"},{"key":"ref46","first-page":"2578","article-title":"In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone","volume":"49","author":"FH Drake","year":"1989","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.fct.2012.12.059","article-title":"TNF\u03b1 and Fas\/FasL pathways are involved in 9-Methoxycamptothecin-induced apoptosis in cancer cells with oxidative stress and G2\/M cell cycle arrest","volume":"55","author":"H Wang","year":"2013","journal-title":"Food Chem Toxicol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e50281","DOI":"10.1371\/journal.pone.0050281","article-title":"ERK1\/2 signaling plays an important role in topoisomerase II poison-induced G2\/M checkpoint activation","volume":"7","author":"RH Kolb","year":"2012","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.onc.1209017","article-title":"Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth","volume":"25","author":"MR Bhonde","year":"2006","journal-title":"Oncogene"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1479-5876-10-250","article-title":"MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy","volume":"10","author":"C Melguizo","year":"2012","journal-title":"J Transl Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10637-013-9968-1","article-title":"Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner","volume":"31","author":"PJ Vlachostergios","year":"2013","journal-title":"Invest New Drugs"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s11064-011-0464-8","article-title":"Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro","volume":"36","author":"L Peig\u00f1an","year":"2011","journal-title":"Neurochem Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0108166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T11:32:30Z","timestamp":1565868750000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0108166"}},"subtitle":[],"editor":[{"given":"Javier S.","family":"Castresana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0108166","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]}}}